Citi analyst

Bristol-Myers Squibb to exit diabetes joint venture - Citi analyst

An announcement made last Thursday of a realignment in priority drug research projects prompted Citi analyst to advise shareholders of a possible interest divestment in diabetes drug joint venture between Bristol-Myers Squibb and AstraZeneca.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics